![]() |
|
|
Vol. 282, Issue 2, 734-746, 1997
Department of Pharmacology, Emory University School of Medicine,
Atlanta, Georgia
Opioids modulate brain dopaminergic function in various experimental
paradigms. This study used the rotational model of behavior in rats
with unilateral 6-hydroxydopamine-induced lesions of the nigrostriatal
pathway to investigate this interaction. Doses of two presynaptically
acting dopaminergic drugs, amphetamine and cocaine, were coadministered
with several doses of the mu opioid agonist, morphine.
Morphine, at 3.0 mg/kg, potentiated rotational behavior induced by each
dose of the stimulants. To determine the receptor specificity of the
actions of morphine, the mu opioid agonists buprenorphine,
fentanyl, levorphanol, meperidine, and methadone, and dextrorphan, the
non-opioid isomer of levorphanol, were administered alone and with 1.0 mg/kg amphetamine. Each of these drugs, as well as morphine, produced
circling behavior on its own. All of the mu opioid agonists
and dextrorphan increased amphetamine-induced turning; the
coadministration of dextrorphan, levorphanol, meperidine, methadone and
morphine with amphetamine produced turning greater than predicted by
simple additivity. To determine whether an opioid receptor was involved
in these interactions, the opioid antagonist, naltrexone, was
administered before the amphetamine/mu opioid receptor
agonist combination. Naltrexone blocked the potentiating effects of
morphine, but not those of the other drugs. Moreover, naltrexone alone
dose-dependently increased amphetamine-induced rotational behavior.
These studies show that some mu opioid receptor agonists can
potentiate stimulant-induced rotational behavior and that blockade of
opioid receptors can also produce a potentiation. The role of
mu opioid receptors in these effects remains unclear.